miR-138-5p inhibits the malignant progression of prostate cancer by targeting FOXC1

被引:0
作者
Dapeng Zhang
Xiaodong Liu
Qingwei Zhang
Xin Chen
机构
[1] Chifengshi Hospital,Department of Urology Surgery
来源
Cancer Cell International | / 20卷
关键词
miR-138-5p; FOXC1; Prostate cancer; Malignant progression;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 104 条
  • [1] Schatten H(2018)Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies Adv Exp Med Biol 1095 1-14
  • [2] Lee DJ(2017)Recent changes in prostate cancer screening practices and epidemiology J Urol 198 1230-1240
  • [3] Mallin K(2014)The genetic epidemiology of prostate cancer and its clinical implications Nat Rev Urol 11 18-31
  • [4] Graves AJ(2017)Prostate cancer: ERSPC calculator recalibrated for China Nat Rev Urol 14 66-440
  • [5] Chang SS(2017)Physical activity and risk of prostate and bladder cancer in China: the South and East China case-control study on prostate and bladder cancer PLoS ONE 12 e178613-339
  • [6] Penson DF(2014)Prostate cancer: measuring PSA Intern Med J 44 433-S272
  • [7] Resnick MJ(2019)Biomarkers for prostate cancer: prostate-specific antigen and beyond Clin Chem Lab Med 58 326-554
  • [8] Eeles R(2014)Management of early-stage prostate cancer Am J Manage Care 20 S260-276
  • [9] Goh C(2014)Current early diagnostic biomarkers of prostate cancer Asian J Androl 16 549-137
  • [10] Castro E(2014)Emerging PSA-based tests to improve screening Urol Clin N Am 41 267-736